Pipeline — registered trials by phase
No registered trials in this stage.
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
— · Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL) · Recruiting · est. 2028-06
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
— · Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer · Recruiting · est. 2029-03
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
— · Familial Adenomatous Polyposis · Recruiting · est. 2027-06
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
— · Unresectable, Locally Advanced, Metastatic Cancers · Recruiting · est. 2028-10-30
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
— · Cerebral Cavernous Malformation · Completed · est. 2025-06-30
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
— · Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) · Recruiting · est. 2028-01
REC-7735 in Participants With Solid Tumors
— · Solid Tumors · Recruiting · est. 2031-01
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Recursion is lead sponsor; 7 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-09-21Current report (material event)
- SCHEDULE 13G2026-08-07SCHEDULE 13G
- 10-Q2026-08-05Quarterly report
- 8-K2026-08-05Current report (material event)
- SCHEDULE 13G2026-07-31SCHEDULE 13G
- SCHEDULE 13G2026-07-31SCHEDULE 13G
- SCHEDULE 13G/A2026-07-29SCHEDULE 13G/A
- 8-K2026-06-18Current report (material event)
- SCHEDULE 13G2026-05-12SCHEDULE 13G
- 10-Q2026-05-06Quarterly report
- 8-K2026-05-06Current report (material event)
- ARS2026-04-30Annual report to holders
- DEFA14A2026-04-30DEFA14A
- DEF 14A2026-04-30Proxy statement
- 8-K2026-04-30Current report (material event)
- SCHEDULE 13G/A2026-04-24SCHEDULE 13G/A
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- 8-K2026-03-25Current report (material event)
- S-82026-02-25Employee stock plan
- 424B52026-02-25Prospectus (offering)
- 10-K2026-02-25Annual report
- 8-K2026-02-25Current report (material event)
- SCHEDULE 13G/A2026-02-05SCHEDULE 13G/A
- SCHEDULE 13G/A2026-02-03SCHEDULE 13G/A
- 8-K2026-01-12Current report (material event)
- SCHEDULE 13D/A2025-12-23SCHEDULE 13D/A
- 8-K2025-12-08Current report (material event)
- 8-K2025-11-26Current report (material event)
- 424B72025-11-26424B7
- 10-Q2025-11-05Quarterly report
- 8-K2025-11-05Current report (material event)
- 8-K2025-10-29Current report (material event)
- 8-K/A2025-08-29Current report (amended)
- 424B72025-08-29424B7
- 10-Q2025-08-05Quarterly report
- 8-K2025-08-05Current report (material event)
- 8-K2025-07-08Current report (material event)
- 424B72025-07-08424B7
- 8-K2025-06-18Current report (material event)
- 8-K2025-06-10Current report (material event)
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.